Skip to main content

Dexcom Value Stock - Dividend - Research Selection

Dexcom

ISIN: US2521311074 , WKN: A0D9T1

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield%
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop a series of next-generation CGM products; and a collaboration with Companion Medical, Inc. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


DexCom (DXCM), Abbott to Launch First FDA Cleared OTC CGMs

2024-07-05
Dexcom (DXCM) and Abbott are set to launch their first FDA-approved over-the-counter CGMs, Stelo and Lingo & Libre Rio, respectively, in the United States this summer.

2 Top Growth Stocks to Buy With $1,000

2024-07-04
These stocks have excellent track records of beating the market.

DexCom's ADA Conference Takeaways: Stelo, CGM Tailwinds Still Intact

2024-07-03
Dexcom's strategy differs from Abbott Labs, focusing on OTC CGM products like Stelo to expand target market and drive sales. Find out why DXCM stock is a Buy.

Calculating The Intrinsic Value Of DexCom, Inc. (NASDAQ:DXCM)

2024-07-01
Key Insights Using the 2 Stage Free Cash Flow to Equity, DexCom fair value estimate is US$113 DexCom's US$113 share...

Why Is DexCom, Inc. (DXCM) One Of The Best Growth Stocks for Billionaire Ray Dalio?

2024-06-28
We recently compiled a list of the 10 Best Growth Stocks To Buy Now According To Billionaire Ray Dalio. In this article, we are going to take a look at where DexCom, Inc. (NASDAQ:DXCM) stands against the other growth stocks. Ray Dalio is one of the most successful investors in Wall Street’s history. He has […]

Dexcom Schedules Second Quarter 2024 Earnings Release and Conference Call for July 25, 2024 at 4: 30 p.m. Eastern Time

2024-06-28
SAN DIEGO - DexCom, Inc. today announced that it plans to release its second quarter 2024 financial results after market close on Thursday, July 25, 2024.Management will hold a conference call to...

Dexcom to lay off 535 employees in California

2024-06-27
A company spokesperson said Dexcom is centralizing its U.S. manufacturing operations in Arizona and repurposing the San Diego facility.

Dexcom Schedules Second Quarter 2024 Earnings Release and Conference Call for July 25, 2024 at 4:30 p.m. Eastern Time.

2024-06-27
SAN DIEGO, June 27, 2024--DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2024 financial results after market close on Thursday, July 25, 2024. Management will hold a conference call to review the company's second quarter 2024 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will be

DexCom (NASDAQ:DXCM) shareholders have earned a 26% CAGR over the last five years

2024-06-27
It hasn't been the best quarter for DexCom, Inc. ( NASDAQ:DXCM ) shareholders, since the share price has fallen 18% in...

Dexcom Schedules Second Quarter 2024 Earnings Release and Conference Call for July 25, 2024 at 4: 30 p.m. Eastern Time.

2024-06-27
DexCom, Inc. today announced that it plans to release its second quarter 2024 financial results after market close on Thursday, July 25, 2024. Management will hold a conference call to review the...